drug development in traumatic brain injury, page-24

I still think Johnson & Johnson is the number one candidate to move on NEU overtime - to many similarities in business & direction to ignore it.

You only have to look at them in late 2011 with their ambitous move with the open R&D program into neuroscience & TBI as the first point of attack making J&J probably one of the first to return back to the graveyard after many gave it away.

"Once the infrastructure is in place, adds Manji, a couple of projects can get started in 2012 and new ones added as the movement grows".

Then to take Perseis into consideration & how it relates, one of J&J's key areas of focus is Oncology (as it is with most majors) couple that with their aquisiton of Centocor (now under Janssen) & Centocor's rep as a leader in monoclonal antibody technology now under their banner.

J&J getting their mittens in with Perseis should the results deliver as expected wouldn't suprise me at all & probably helps to get their close association as the later stage projects progress.